Generic Anjeso Availability
Last updated on Apr 10, 2025.
Anjeso is a brand name of meloxicam, approved by the FDA in the following formulation(s):
ANJESO (meloxicam - solution;intravenous)
-
Manufacturer: BAUDAX
Approval date: February 20, 2020
Strength(s): 30MG/ML (30MG/ML) (discontinued) [RLD]
All of the above formulations have been discontinued.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Anjeso. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Nanoparticulate meloxicam formulations
Patent 10,709,713
Issued: July 14, 2020
Inventor(s): Cooper Eugene R. & Ryde Tuula & Pruitt John & Kline Laura
Assignee(s): BAUDAX BIO, INC.The present invention is directed to nanoparticulate compositions comprising meloxicam particles having an effective average particle size of less than about 2000 nm.
Patent expiration dates:
- May 26, 2030✓
- May 26, 2030
-
Method of treating pain in elderly patients with mild renal impairment
Patent 10,881,663
Issued: January 5, 2021
Inventor(s): Mack Randall J. & McCallum Stewart & Gomez Alexis & Freyer Alex
Assignee(s): BAUDAX BIO, INC.The present disclosure relates to administration of meloxicam intravenously, for treatment of pain, in patients who are at least 65 years old and have mild renal impairment, which can provide fast onset of pain relief suitable for management of acute pain as well as moderate to severe pain.
Patent expiration dates:
- March 8, 2039✓
- March 8, 2039
-
Reduction of flake-like aggregation in nanoparticulate active agent compositions
Patent 11,253,478
Issued: February 22, 2022
Inventor(s): Ryde Niels P. & Snyder Peter & Liu Wei & Slifer David M.
Assignee(s): Alkermes Pharma Ireland LimitedThis invention is directed to reduction of flake-like aggregation in nanoparticulate compositions. Also encompassed by the invention are compositions comprising a nanoparticulate active agent, at least one surface stabilizer and a flake-like aggregation reducing agent, such as a buffer and a sugar. The nanoparticulate active agent compositions comprise particles of the active agent having an effective average particle size of less than about 2000 nm.
Patent expiration dates:
- May 26, 2030✓✓
- May 26, 2030
-
Methods of administering intravenous meloxicam in a bolus dose
Patent 11,458,145
Issued: October 4, 2022
Inventor(s): Mack; Randall J. et al.
Assignee(s): BAUDAX BIO, INC. (Malvern, PA)The present disclosure relates to meloxicam bolus formulations and methods of administering the same intravenously, for treatment of pain, which can provide fast onset of pain relief suitable for management of acute moderate to severe pain.
Patent expiration dates:
- March 8, 2039✓
- March 8, 2039
-
Reduction of flake-like aggregation in nanoparticulate active agent compositions
Patent 9,974,746
Issued: May 22, 2018
Inventor(s): Ryde Niels P. & Snyder Peter & Liu Wei & Slifer David M.
Assignee(s): Alkermes Pharma Ireland LimitedThis invention is directed to reduction of flake-like aggregation in nanoparticulate compositions. Also encompassed by the invention are compositions comprising a nanoparticulate active agent, at least one surface stabilizer and a flake-like aggregation reducing agent, such as a buffer and a sugar. The nanoparticulate active agent compositions comprise particles of the active agent having an effective average particle size of less than about 2000 nm.
Patent expiration dates:
- May 26, 2030✓
- May 26, 2030
More about Anjeso (meloxicam)
- Anjeso consumer information
- Check interactions
- Compare alternatives
- Latest FDA alerts (5)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: Nonsteroidal anti-inflammatory drugs
- Breastfeeding
- En español
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.